AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31502323 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine combined with sufentanil (RS1 group)
Number of subjects: 160
Study 31502323 — intervention group
Group type: COMPARATOR
Intervention: Ropivacaine combined with sufentanil (RS2 group)
Number of subjects: 160
Study 31502323 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine combined with dexmedetomidine (RD2 group)
Number of subjects: 160
Study 28640385 — intervention group
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin (BV) consolidation therapy
Number of subjects: 1
Study 26455521 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg daily rosuvastatin
Number of subjects: 147
Study 26455521 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 147
Study 23292368 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Darn Repair (MDR)
Number of subjects: 227
Study 23292368 — intervention group
Group type: COMPARATOR
Intervention: Lichtenstein Procedure (LP)
Number of subjects: 227
Study 22143452 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse management plus home blood pressure monitor
Number of subjects: 416
Study 22143452 — intervention group
Group type: COMPARATOR
Intervention: Home blood pressure monitor only
Number of subjects: 416
Study 22143452 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 416
Study 19317824 — intervention group
Group type: EXPERIMENTAL
Intervention: Staged Diabetes Management (SDM)
Number of subjects: 200
Study 19317824 — intervention group
Group type: COMPARATOR
Intervention: No protocols for diabetes care (Control)
Number of subjects: 200
Study 17302926 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral hygiene measures provided by dental hygienists once every 3 weeks (Group A)
Number of subjects: 130
Study 17302926 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing staff provided daily oral hygiene after hands-on instructions (Group B)
Number of subjects: 130
Study 17302926 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group C)
Number of subjects: 130
Study 15145325 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-daily isophane insulin (Group 2)
Number of subjects: 57
Study 15145325 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal/bolus isophane/lispro insulin (Group 3)
Number of subjects: 57
Study 15145325 — intervention group
Group type: COMPARATOR
Intervention: Continue tablets (Group 1)
Number of subjects: 57
Study 11163559 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine infusion (200 microg/kg) before aortic cross‐clamp
Number of subjects: 20
Study 11163559 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal saline injection)
Number of subjects: 20
Study 9833044 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy for eradication of Helicobacter pylori for one week
Number of subjects: 125
Study 9833044 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 125
Study 7854555 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive family history for CHD
Number of subjects: 130
Study 7854555 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 130
Study 28486329 — intervention group
Group type: EXPERIMENTAL
Intervention: CoQ10 supplementation (300 mg·d)
Number of subjects: 36
Study 28486329 — intervention group
Group type: EXPERIMENTAL
Intervention: Precooling (immersion in water at 18 ± 0.5° C)
Number of subjects: 36
Study 28486329 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplementation with precooling
Number of subjects: 36
Study 28486329 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 36
Study 28764674 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical pessary
Number of subjects: 352
Study 28764674 — intervention group
Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 352
Study 26222430 — intervention group
Group type: EXPERIMENTAL
Intervention: Texting while walking
Number of subjects: 30
Study 26222430 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive distraction while texting and walking
Number of subjects: 30
Study 26222430 — intervention group
Group type: EXPERIMENTAL
Intervention: Texting and cognitive distraction
Number of subjects: 30
Study 26222430 — intervention group
Group type: COMPARATOR
Intervention: Normal walking
Number of subjects: 30
Study 24130355 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple daily insulin analog injections
Number of subjects: 18
Study 24130355 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion therapy
Number of subjects: 18
Study 24130355 — intervention group
Group type: COMPARATOR
Intervention: Conventional glucose monitoring
Number of subjects: 18
Study 24130355 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time continuous glucose monitoring
Number of subjects: 18
Study 21354608 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5% hydrolyzed sodium trimetaphosphate (STMP) applied to artificial carious lesions; bonded with One-Step adhesive and non-adhesive infiltrated specimens; remineralized in PAA-containing simulated body fluid for 4 months.
Number of subjects: 0
Study 21354608 — intervention group
Group type: COMPARATOR
Intervention: Control groups without PAA and STMP; no treatment applied.
Number of subjects: 0
Study 19695194 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambroxol (4.5 mg/kg in 10 mL normal saline by intravenous injection after skin incision)
Number of subjects: 40
Study 19695194 — intervention group
Group type: COMPARATOR
Intervention: Control (10 mL normal saline)
Number of subjects: 40
Study 17383313 — intervention group
Group type: EXPERIMENTAL
Intervention: On-pump CABG
Number of subjects: 300
Study 17383313 — intervention group
Group type: COMPARATOR
Intervention: Off-pump CABG
Number of subjects: 300
Study 15562083 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-injection paravertebral block (PVB) with bupivacaine 5 mg/mL (1.5 mg/kg)
Number of subjects: 60
Study 11566623 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin-2 therapy
Number of subjects: 0
Study 11566623 — intervention group
Group type: COMPARATOR
Intervention: Control (HAART)
Number of subjects: 0
Study 9785067 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 34
Study 9785067 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 34
Study 7869705 — intervention group
Group type: EXPERIMENTAL
Intervention: Bogus pipeline condition
Number of subjects: 0
Study 7869705 — intervention group
Group type: COMPARATOR
Intervention: No bogus pipeline condition
Number of subjects: 0
Study 3202506 — intervention group
Group type: EXPERIMENTAL
Intervention: Hot dry air
Number of subjects: 16
Study 3202506 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold air
Number of subjects: 16
Study 3202506 — intervention group
Group type: EXPERIMENTAL
Intervention: Room temperature air
Number of subjects: 16
Study 3202506 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal subjects)
Number of subjects: 16
Study 3202506 — intervention group
Group type: COMPARATOR
Intervention: Control group (asthmatic subjects)
Number of subjects: 16
Study 31929203 — intervention group
Group type: EXPERIMENTAL
Intervention: Kangaroo care (n = 30)
Number of subjects: 60
Study 31929203 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group, n = 30)
Number of subjects: 60
Study 30672234 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-snake moxibustion therapy, applied on acupoints of the governor vessel (Dazhui to Yaoshu) and bilateral Jiaji, once a day for 7 days, 4 courses total.
Number of subjects: 60
Study 30672234 — intervention group
Group type: COMPARATOR
Intervention: Routine western medication (salazosulfapyridine and NSAIDs), for 7 days, 4 courses total.
Number of subjects: 60
Study 28108076 — intervention group
Group type: EXPERIMENTAL
Intervention: Alveolar recruitment maneuver with positive end-expiratory pressure and low tidal volumes
Number of subjects: 90
Study 28108076 — intervention group
Group type: COMPARATOR
Intervention: Control group (no alveolar recruitment maneuvers)
Number of subjects: 90
Study 26157076 — intervention group
Group type: EXPERIMENTAL
Intervention: Melphalan, prednisone, and thalidomide (MPT‐T)
Number of subjects: 306
Study 26157076 — intervention group
Group type: COMPARATOR
Intervention: Melphalan, prednisone, and lenalidomide (mPR‐R)
Number of subjects: 306
Study 24085784 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir
Number of subjects: 21
Study 24085784 — intervention group
Group type: EXPERIMENTAL
Intervention: Adefovir
Number of subjects: 21
Study 24085784 — intervention group
Group type: COMPARATOR
Intervention: Healthy donors
Number of subjects: 21
Study 21961433 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline tibia BML volume
Number of subjects: 107
Study 21961433 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline femur BML volume
Number of subjects: 107
Study 21961433 — intervention group
Group type: EXPERIMENTAL
Intervention: Approximate BML volume changes by region
Number of subjects: 107
Study 18242338 — intervention group
Group type: EXPERIMENTAL
Intervention: Methimazole (n = 25)
Number of subjects: 43
Study 18242338 — intervention group
Group type: EXPERIMENTAL
Intervention: Propylthiouracil (n = 18)
Number of subjects: 43
Study 16845251 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase
Number of subjects: 184
Study 16845251 — intervention group
Group type: EXPERIMENTAL
Intervention: Metalyze
Number of subjects: 184
Study 16845251 — intervention group
Group type: EXPERIMENTAL
Intervention: Reteplase
Number of subjects: 184
Study 12809959 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemirolast
Number of subjects: 93
Study 11265802 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal myocardial revascularisation
Number of subjects: 0
Study 11265802 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiogenic growth factors
Number of subjects: 0
Study 8804803 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate 50 mg/m2 intramuscularly followed by misoprostol 800 micrograms vaginally
Number of subjects: 300
Study 1626037 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (250mg)
Number of subjects: 48
Study 1626037 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 6383735 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 percent amcinonide cream
Number of subjects: 33
Study 6383735 — intervention group
Group type: COMPARATOR
Intervention: 0.1 percent halcinonide cream
Number of subjects: 33
Study 30182359 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 μg/day sodium selenite (GI)
Number of subjects: 102
Study 30182359 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg vitamin C/day (GII)
Number of subjects: 102
Study 30182359 — intervention group
Group type: COMPARATOR
Intervention: Placebo (GIII)
Number of subjects: 102
Study 30130351 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg ulipristal acetate daily for 7 days
Number of subjects: 65
Study 30130351 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 27456689 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided Internet-delivered cognitive behavioural therapy (CBT) program, consisting of four sessions including psychoeducation, physical activity, and relaxation.
Number of subjects: 15
Study 27456689 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 15
Study 24722219 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacy-based intervention providing HIV risk reduction and social/medical services information during syringe sale
Number of subjects: 88
Study 24722219 — intervention group
Group type: COMPARATOR
Intervention: Primary control (recruited IDU syringe customers only)
Number of subjects: 88
Study 24722219 — intervention group
Group type: COMPARATOR
Intervention: Secondary control (did not recruit IDUs or deliver intervention activities)
Number of subjects: 88
Study 23164366 — intervention group
Group type: EXPERIMENTAL
Intervention: POSE program (Promotion Of Sustained Employability)
Number of subjects: 0
Study 20080842 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteoporosis treatment (risedronate, strontium ranelate, zoledronic acid, denosumab)
Number of subjects: 0
Study 17396084 — intervention group
Group type: EXPERIMENTAL
Intervention: Video movie about liver biopsy
Number of subjects: 67
Study 17396084 — intervention group
Group type: COMPARATOR
Intervention: Standard information delivery (no video)
Number of subjects: 67
Study 15361699 — intervention group
Group type: EXPERIMENTAL
Intervention: Leptospirosis ARF patients (group 1, P(creat) >442 micromol/l)
Number of subjects: 35
Study 15361699 — intervention group
Group type: EXPERIMENTAL
Intervention: Leptospirosis ARF patients (group 2, P(creat) < or =442 micromol/l)
Number of subjects: 35
Study 15361699 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups of leptospirosis ARF patients
Number of subjects: 35
Study 15361699 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers
Number of subjects: 35
Study 11523637 — intervention group
Group type: EXPERIMENTAL
Intervention: Unwanted sexual activity during childhood (USC)
Number of subjects: 3346
Study 9565284 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 5 (added semi-annual prophylaxis)
Number of subjects: 297
Study 9565284 — intervention group
Group type: COMPARATOR
Intervention: Group 1 (control group)
Number of subjects: 297
Study 9565284 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2 (behavioral training)
Number of subjects: 297
Study 9565284 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 3 (added weekly chlorhexidine rinse)
Number of subjects: 297
Study 9565284 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 4 (added semi-annual fluoride varnish)
Number of subjects: 297
Study 9565284 — intervention group
Group type: EXPERIMENTAL
Intervention: Groups 3, 4, and 5 combined
Number of subjects: 297
Study 9565284 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-efficacy
Number of subjects: 297
Study 8140926 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate sodium (0, 5, 20, and 40 mg) for 6 weeks
Number of subjects: 65
Study 8140926 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 3055001 — intervention group
Group type: EXPERIMENTAL
Intervention: Open group psychotherapy
Number of subjects: 0
Study 3055001 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed group psychotherapy
Number of subjects: 0
Study 31025287 — intervention group
Group type: EXPERIMENTAL
Intervention: U13 → C13 mutation in the NA gene 3′UTR
Number of subjects: 0
Study 31025287 — intervention group
Group type: EXPERIMENTAL
Intervention: Other mutations within the UTR
Number of subjects: 0
Study 30200910 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 cycles of docetaxel+oxaliplatin+capecitabine (DOC)
Number of subjects: 0
Study 30200910 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 cycles of DOC followed by chemoradiotherapy (45Gy in combination with weekly paclitaxel and carboplatin)
Number of subjects: 0
Study 30200910 — intervention group
Group type: EXPERIMENTAL
Intervention: chemoradiotherapy
Number of subjects: 0
Study 30200910 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 26832339 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 58
Study 26832339 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 24594871 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (24 IU or 40.32 μg)
Number of subjects: 18
Study 24594871 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 18
Study 23075357 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetyl salicylic acid (ASA) and terbutaline for 9 weeks after embryo transfer and around the time of embryo transfer, respectively.
Number of subjects: 167
Study 23075357 — intervention group
Group type: COMPARATOR
Intervention: No adjuvant medication (Control group).
Number of subjects: 167
Study 19411457 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented repair with a down‐turned gastrocnemius fascia flap
Number of subjects: 60
Study 19411457 — intervention group
Group type: COMPARATOR
Intervention: Simple repair (end‐to‐end suture repair with Krackow locking loop technique)
Number of subjects: 60
Study 19411457 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented repair
Number of subjects: 60
Study 19411457 — intervention group
Group type: COMPARATOR
Intervention: Simple repair
Number of subjects: 60
Study 19411457 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 17241691 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearlink Y‐type extension sets
Number of subjects: 50
Study 17241691 — intervention group
Group type: COMPARATOR
Intervention: Three‐way stopcock luers with standard caps
Number of subjects: 50
Study 15619404 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose paclitaxel-eluting stents
Number of subjects: 81
Study 15619404 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose paclitaxel-eluting stents
Number of subjects: 81
Study 15619404 — intervention group
Group type: COMPARATOR
Intervention: Placebo stents
Number of subjects: 81
Study 15619404 — intervention group
Group type: EXPERIMENTAL
Intervention: IVUS percent neointima volume obstruction
Number of subjects: 81
Study 15619404 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiographic late lumen loss
Number of subjects: 81
Study 15619404 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up diameter stenosis
Number of subjects: 81
Study 12688622 — intervention group
Group type: EXPERIMENTAL
Intervention: Stringent environmental control (allergen impermeable covers, hot washing of bedding weekly, HEPA vacuum cleaner, hard floor for nursery)
Number of subjects: 995
Study 12688622 — intervention group
Group type: COMPARATOR
Intervention: Normal regime (no stringent environmental control)
Number of subjects: 995
Study 10097222 — intervention group
Group type: EXPERIMENTAL
Intervention: PTCA
Number of subjects: 1128
Study 7581965 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral GHRP-6 (300 micrograms/kg)
Number of subjects: 13
Study 7581965 — intervention group
Group type: COMPARATOR
Intervention: Intravenous GHRH (GHRH-29, 1 microgram/kg)
Number of subjects: 13
Study 2101864 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg fluconazole per day orally
Number of subjects: 40
Study 2101864 — intervention group
Group type: COMPARATOR
Intervention: 800 mg amphotericin B per day orally
Number of subjects: 40
Study 386062 — intervention group
Group type: EXPERIMENTAL
Intervention: labetalol
Number of subjects: 18
Study 386062 — intervention group
Group type: EXPERIMENTAL
Intervention: bendrofluazide
Number of subjects: 18
Study 386062 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 18
Study 31891860 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol intake (breath alcohol concentration of 0.08 g/dL)
Number of subjects: 15
Study 31891860 — intervention group
Group type: COMPARATOR
Intervention: Placebo beverage
Number of subjects: 15
Study 31049919 — intervention group
Group type: EXPERIMENTAL
Intervention: Stabilization exercise program for six weeks
Number of subjects: 39
Study 31049919 — intervention group
Group type: COMPARATOR
Intervention: Radiofrequency denervation
Number of subjects: 39
Study 29142554 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (50,000 units per day orally)
Number of subjects: 100
Study 29142554 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 25296344 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation (NMES) of the quadriceps muscle, twice daily for 7±1 days
Number of subjects: 6
Study 25296344 — intervention group
Group type: COMPARATOR
Intervention: Control leg (non-stimulated)
Number of subjects: 6
Study 25296344 — intervention group
Group type: EXPERIMENTAL
Intervention: NMES
Number of subjects: 6
Study 24912899 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 years of trastuzumab (n = 1,673)
Number of subjects: 5102
Study 24912899 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 year of trastuzumab (n = 1,682)
Number of subjects: 5102
Study 24912899 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 years of trastuzumab
Number of subjects: 5102
Study 24912899 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 year of trastuzumab
Number of subjects: 5102
Study 24912899 — intervention group
Group type: COMPARATOR
Intervention: Observation (n = 1,744)
Number of subjects: 5102
Study 24912899 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 5102
Study 22746261 — intervention group
Group type: EXPERIMENTAL
Intervention: Teen Online Problem Solving (TOPS)
Number of subjects: 41
Study 22746261 — intervention group
Group type: COMPARATOR
Intervention: Internet Resource Comparison (IRC)
Number of subjects: 41
Study 18855801 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 1200 mg
Number of subjects: 33
Study 18855801 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 17300627 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine (CQ) prophylaxis (500 mg phosphate weekly)
Number of subjects: 1000
Study 17300627 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1000
Study 17300627 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine (CQ) prophylaxis
Number of subjects: 1000
Study 15199346 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-dose tenecteplase plus enoxaparin
Number of subjects: 6095
Study 15199346 — intervention group
Group type: EXPERIMENTAL
Intervention: Half-dose tenecteplase plus abciximab
Number of subjects: 6095
Study 15199346 — intervention group
Group type: COMPARATOR
Intervention: Full-dose tenecteplase plus unfractionated heparin
Number of subjects: 6095
Study 15199346 — intervention group
Group type: COMPARATOR
Intervention: Comparison of enoxaparin versus heparin
Number of subjects: 6095
Study 15199346 — intervention group
Group type: COMPARATOR
Intervention: Comparison of abciximab versus heparin
Number of subjects: 6095
Study 11779753 — intervention group
Group type: EXPERIMENTAL
Intervention: L-bandage
Number of subjects: 68
Study 11779753 — intervention group
Group type: COMPARATOR
Intervention: S-bandage
Number of subjects: 68
Study 9521232 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (50 mg)
Number of subjects: 27271
Study 9521232 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta carotene (20 mg)
Number of subjects: 27271
Study 9521232 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27271